Jonathan Trent
Medical Oncology · Miami, FLNPI 1780770552
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,846 of the $102,259 with a category attached, or 64.4%. 21 manufacturers reported payments, led by Bayer at 30.4% of the total. Reporting peaked in 2024 at $28,127 and has fallen 67.3% since, to $9,189 in 2025. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $798.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$31K
- Daiichi Sankyo Inc.$28K
- Deciphera Pharmaceuticals Inc.$16K
- Boehringer Ingelheim$9K
- Ipsen Biopharmaceuticals, Inc$7K
- Aadi Bioscience, Inc.$4K
- plus $8K from 15 others
Across 614 payments — averaging $10,706 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$3.1M
- Servier Pharmaceuticals LLC$1.5M
- Servier Bioinnovation$533K
- Pfizer$443K
- Blueprint Medicines Corporation$370K
- Merck$262K
- plus $382K from 6 others
What the payments were for
- Consulting fees$65,84664%
- Speaking & faculty fees$25,32925%
- Travel & lodging$7,5147%
- Food & beverage$3,4643%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 26 | $31,081 |
| Daiichi Sankyo Inc. | 33 | $27,528 |
| Deciphera Pharmaceuticals Inc. | 24 | $15,968 |
| Boehringer Ingelheim | 5 | $9,138 |
| Ipsen Biopharmaceuticals, Inc | 5 | $6,539 |
| Aadi Bioscience, Inc. | 8 | $4,383 |
| Servier Bioinnovation | 2 | $2,865 |
| Servier Pharmaceuticals LLC | 1 | $2,800 |
| Springworks Therapeutics, Inc. | 2 | $1,089 |
| Exelixis Inc. | 1 | $172 |
| Tempus AI, Inc | 2 | $163 |
| GSK | 2 | $146 |
| Epizyme, Inc. | 1 | $85 |
| Pfizer | 5 | $81 |
| Amgen | 2 | $46 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
| Lilly USA, LLC | 1 | $39 |
| Seagen Inc. | 2 | $28 |
| Foundation Medicine, Inc. | 1 | $28 |
| AstraZeneca | 2 | $26 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,259 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 12 | $13,278 |
| Tramadol Hcl | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Sarbajit MukherjeeMiami$232K
- Bruna Pellini FerreiraMiami$158K
- Coral OlazagastiMiami$134K
- Gilberto LopesMiami$99K
- Craig MoskowitzMiami$94K
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.